Alector

Alector is a clinical-stage biotechnology company based in South San Francisco, California, founded in 2013. The company focuses on developing innovative immuno-neurology therapies to address neurodegenerative diseases, including frontotemporal dementia, Alzheimer’s, and Parkinson’s disease. Alector aims to erase these diseases by utilizing insights from human genetics, neuroscience, and immunology to create therapies that restore immune and nerve cell function. The company specializes in drug development, protein engineering, and antibody discovery, employing proprietary technology like the Alector Brain Carrier (ABC) to enhance therapeutic delivery to the brain. Alector's pipeline features antibody drug candidates such as AL001 for frontotemporal dementia and AL002 for Alzheimer’s disease, with AL001 currently in late-stage clinical trials. Alector collaborates with major pharmaceutical companies, including AbbVie and GSK, to co-develop its therapeutic candidates, reflecting strong industry validation. The company also operates a manufacturing facility in Milpitas, California, to support its clinical and commercial activities.